Physician's Choice SOC

DRUG2 trials

Sponsors

Rakuten Medical, Inc., Guangdong Association of Clinical Trials

Conditions

Head and Neck CancerNSCLC

Phase 3

ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

Active, not recruitingNCT03769506

Rakuten Medical, Inc.Head and Neck Cancer

Start: 2019-05-09End: 2025-12-31Updated: 2025-01-16

Unknown Phase

RGL-270 + ICI in Advanced NSCLC

RecruitingNCT07652125

Guangdong Association of Clinical TrialsNSCLC

Start: 2025-10-25End: 2027-12-31Target: 40Updated: 2026-06-30

Related Papers

A phase 3, randomized, double-arm, open-label, controlled study of ASP-1929 photoimmunotherapy (PIT) versus physician’s choice standard of care (SOC) for patients with locoregional, recurrent head and neck squamous cell carcinoma (HNSCC).

Journal of Clinical Oncology2026-05-27

SNAP-Tag-Based Recombinant Photoimmunotherapeutic Agents for the Selective Detection and Killing of Light-Accessible Melanotransferrin-Expressing Melanoma and Triple-Negative Breast Cancer.

2025-05-011 citations

Recent Advances in Localized Immunomodulation Technology: Application of NIR-PIT toward Clinical Control of the Local Immune System.

2023-02-073 citations

Phase 1/2a, open‐label, multicenter study of <scp>RM</scp>‐1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma

Head & Neck2021-10-09156 citations

A phase I, single-center, open-label study of RM-1929 photoimmunotherapy in Japanese patients with recurrent head and neck squamous cell carcinoma.

2021-06-2481 citations

Reducing the immunosuppressive tumor microenvironment enhances photoimmunotherapy efficacy

EBioMedicine2021-05-011 citations

Near-infrared photoimmunotherapy of cancer: a new approach that kills cancer cells and enhances anti-cancer host immunity

International Immunology2020-05-27128 citations

Near infrared photoimmunotherapy: a new type of immune theranostic technology for cancer

2020-04-013 citations

Antibodies to watch in 2020.

2020-01-01328 citations

Near-Infrared Photoimmunotherapy of Cancer.

2019-07-23317 citations

A global phase III multicenter, randomized, double-arm, open label trial of ASP-1929 photoimmunotherapy versus physician’s choice standard of care for the treatment of patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC).

Journal of Clinical Oncology2019-05-2010 citations